Filtered By:
Drug: Coumadin
Management: Medicare
This page shows you your search results in order of date.
Order by Relevance | Date
Total 104 results found since Jan 2013.
Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation
ConclusionsThe proportions of patients with non-valvular atrial fibrillation who were not prescribed an oral anticoagulant decreased but remained high. We observed an increase in direct oral anticoagulant use that coincided with decreased incidence of clinical outcomes as well as decreasing total healthcare costs.
Source: Journal of Thrombosis and Thrombolysis - August 2, 2023 Category: Hematology Source Type: research
Predicting treatment effects of a new-to-market drug in clinical practice based on phase III randomized trial results
Clin Pharmacol Ther. 2023 Jun 26. doi: 10.1002/cpt.2983. Online ahead of print.ABSTRACTTrial results may not be generalizable to target populations treated in clinical practice with different distributions of baseline characteristics that modify the treatment effect. We used outcome models developed with trial data to predict treatment effects in Medicare populations. We used data from the Randomized Evaluation of Long-Term Anticoagulation Therapy trial (RE-LY), which investigated the effect of dabigatran vs. warfarin on stroke or systemic embolism (stroke/SE) among patients with atrial fibrillation. We developed outcome m...
Source: Clinical Pharmacology and Therapeutics - June 27, 2023 Category: Drugs & Pharmacology Authors: HoJin Shin Shirley V Wang Dae Hyun Kim Ethan Alt Mufaddal Mahesri Lily G Bessette Sebastian Schneeweiss Mehdi Najafzadeh Source Type: research
Long Term Outcomes and Anticoagulation in Mitral Valve Surgery - A Report from the Society of Thoracic Surgeons Database
CONCLUSIONS: Anticoagulation was used in less than half of mitral valve surgery. In MVrep patients, warfarin was associated with increased bleeding and was not protective against either stroke or mortality. In BMVR patients, warfarin was associated with a modest survival benefit, increased bleeding and equivalent stroke risk. NOAC was associated with increased adverse outcomes.PMID:37308066 | DOI:10.1016/j.athoracsur.2023.05.025
Source: The Annals of Thoracic Surgery - June 12, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Thomas A Schwann Andrew M Vekstein Daniel T Engelman Dylan Thibault Joanna Chikwe Milo Engoren Mario Gaudino Sreekanth Vemulapalli Vinod Thourani Gorav Ailawadi Anthony Rousou Robert H Habib Source Type: research
Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation
CONCLUSIONS: Older adults with cancer and atrial fibrillation exposed to DOACs had similar risks of stroke and systemic embolism and major bleeding as those exposed to warfarin. Relative to warfarin, DOAC use was associated with a similar risk of cardiovascular death and a lower risk of all-cause death.PMID:36453260 | DOI:10.1161/CIRCOUTCOMES.122.008951
Source: Cancer Control - December 1, 2022 Category: Cancer & Oncology Authors: Hemalkumar B Mehta Huijun An Shirin Ardeshirrouhanifard Mukaila A Raji G Caleb Alexander Jodi B Segal Source Type: research
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study
CONCLUSIONS: Over 12 months after initiation, apixaban and dabigatran conferred progressive increases in event free time for stroke/SE and MB vs warfarin, whereas rivaroxaban conferred an increase in stroke/SE-free time but a loss in MB-free time vs warfarin.PMID:36456387 | DOI:10.1016/j.ejim.2022.10.021
Source: European Journal of Internal Medicine - December 1, 2022 Category: Internal Medicine Authors: Steven Deitelzweig Allison Keshishian Amiee Kang Aaron Jenkins Nipun Atreja Patricia Schuler Jenny Jiang Huseyin Yuce Xiaoxi Sun Gregory Y H Lip Source Type: research
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population: updated analysis
CONCLUSIONS: This real-world analysis showed DOACs to be associated with lower risk of stroke/SE and major bleeding, and lower medical costs compared to warfarin. Among them, only apixaban appears to be associated with a significantly lower risk of all three outcomes collectively: stroke/SE, major bleeding, and lower related medical costs compared to warfarin.PMID:35993487 | DOI:10.1080/03007995.2022.2115772
Source: Current Medical Research and Opinion - August 22, 2022 Category: Research Authors: Alpesh Amin Allison Keshishian Dionne M Hines Oluwaseyi Dina Hannah Le Lisa Rosenblatt Xianchen Liu Qisu Zhang Lien Vo Source Type: research
Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database
ConclusionsAlthough OAC therapy prescription is the standard of care for stroke prevention in AF patients, its overall utilization is still low among Medicare patients ≥ 65 years old, with specific patient characteristics that predict underutilization.
Source: Journal of Interventional Cardiac Electrophysiology - July 9, 2022 Category: Cardiology Source Type: research
Group based trajectory modeling to assess adherence to oral anticoagulants among atrial fibrillation patients with comorbidities: a retrospective study
ConclusionAdherence to oral anticoagulants is suboptimal. Interventions tailored according to past adherence trajectories may be effective in improving patient ’s adherence.
Source: International Journal of Clinical Pharmacy - July 1, 2022 Category: Drugs & Pharmacology Source Type: research
